[Benefit assessment of biotechnologically produced drugs for the treatment of rheumatoid arthritis]

Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018004499
German
Original Title: Biotechnologisch hergestellte Wirkstoffe bei rheumatoider Arthritis
Details
Project Status: Completed
Year Published: 2019
English language abstract: There is no English language summary available
Publication Type: Full HTA
Country: Germany
MeSH Terms
  • Arthritis, Rheumatoid
  • Biological Products
  • Abatacept
  • Adalimumab
  • Certolizumab Pegol
  • Etanercept
  • Infliximab
  • Rituximab
  • Antirheumatic Agents
  • Interleukin 1 Receptor Antagonist Protein
Keywords
  • Abatacept
  • Adalimumab
  • Anakinra
  • Certolizumab Pegol
  • Etanercept
  • Golimumab
  • Infliximab
  • Rituximab
  • Tocilizumab
  • Arthritis - Rheumatoid
  • Benefit Assessment
  • Systematic Review
Contact
Organisation Name: Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address: IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email: berichte@iqwig.de
Copyright: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.